Sionna Therapeutics, Inc. (NASDAQ:SION) released data from its Phase 1 trials of SION-719 and SION-451, the company’s ...

Sionna’s shares are scheduled to begin trading on the Nasdaq Global Market on February 7, 2025 under the ticker symbol "SION.

Sionna said these molecules, two correctors and one potentiator, could be combined with its NBD1 stabilizers. Prior to the ...

Sionna has ongoing Phase 1 trials of its two NBD1 stabilizers, SION-719 and SION-451. As of Dec. 31, 2024 the company had 35 full-time employees.

Sionna plans to advance SION-719 to a Phase 2a proof-of-concept add-on to standard of care trial in cystic fibrosis patients, and SION-451 to a Phase 1 healthy volunteer dual combination trial .

Sionna has its own TMD1-directed corrector, SION-676, in preclinical development, plus an ICL4-targeted candidate, SION-109, in phase 1. The expansion of the pipeline gives Sionna a choice to make.

Sionna Therapeutics, Inc. has announced the presentation of promising preclinical data at the 48th European Cystic Fibrosis Conference in Milan, showing that its nucleotide-binding domain 1 (NBD1 ...

TD Cowen initiated coverage of Sionna Therapeutics (SION) with a Buy rating. Sionna’s pipeline of cystic fibrosis therapies directly target NBD1, which was previously thought to be ...

Sionna Therapeutics aims to raise $100 million in an IPO for cystic fibrosis drugs, backed by venture capital, targeting a growing $22.8 billion therapeutics market. Read the IPO report here ...

Sionna plans to advance SION-719 to a Phase 2a proof-of-concept add-on to standard of care trial in cystic fibrosis patients, and SION-451 to a Phase 1 healthy volunteer dual combination trial .

Sionna said these molecules, two correctors and one potentiator, could be combined with its NBD1 stabilizers. Prior to the IPO, Sionna said it had raised about $330 million from investors.